Phase II study of tamoxifen in patients with disseminated malignant melanoma

E. T. Creagan, J. N. Ingle, S. J. Green, D. L. Ahmann, N. S. Jiang

Research output: Contribution to journalArticle

34 Scopus citations

Abstract

Twenty-five evaluable, ambulatory outpatients with disseminated malignant melanoma received tamoxifen at a dose of 40 mg orally each day. None of the patients had an objective regression and approximately 70% had disease progression within 30 days of starting treatment, including two patients with detectable estrogen receptor titers. Median survival time and time to progression were 4 months and 1 month respectively. Performance score was the most significant covariate for survival time (P<0.01) and time to progression (P = 0.02).

Original languageEnglish (US)
Pages (from-to)199-201
Number of pages3
JournalCancer Treatment Reports
Volume64
Issue number2-3
StatePublished - Nov 18 1980

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of tamoxifen in patients with disseminated malignant melanoma'. Together they form a unique fingerprint.

  • Cite this

    Creagan, E. T., Ingle, J. N., Green, S. J., Ahmann, D. L., & Jiang, N. S. (1980). Phase II study of tamoxifen in patients with disseminated malignant melanoma. Cancer Treatment Reports, 64(2-3), 199-201.